Health management program: Factors influencing completion of therapy with high-dose interferon alfa-2b for high-risk melanoma

Current Oncology

Volumn 15, Issue 1, 2008, Pages 36-41

  Levesque, Nancy ^a   Mitchinson, K ^b   Lawrie, Debbie ^c   Fedorak, Leslie ^d   MacDonald, D ^e   Normand, C ^f   Pouliot, Jean Franćois ^e,g  

^a JURAVINSKI CANCER CENTRE   (Canada)

^b Royal Victoria Hospital Barrie   (Canada)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^d CROSS CANCER INSTITUTE   (Canada)

^e Centre Hospitalier des Vallées de l'Outaouais ^*  (Canada)

^f Centre Hospitalier des Vallées de l'Outaouais   (Canada)

^g Schering Plough Canada   (Canada)

Author keywords

Adherence; Clinical trial; Interferon alfa 2b; Melanoma

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON;

ADJUVANT THERAPY; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLOOD TOXICITY; CANCER MORTALITY; CANCER PREVENTION; CANCER SURGERY; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DOSE TIME EFFECT RELATION; DRUG INDUCED HEADACHE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FLUID INTAKE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; LIVER DYSFUNCTION; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MALE; MELANOMA; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; ONCOLOGY NURSING; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT MONITORING; RECURRENCE RISK; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION;

EID: 51649093304     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.2008.200     Document Type: Article

References (17)

1. Canadian Cancer Society and the National Cancer Institute of Canada. Canadian Cancer Statistics 2006. Toronto: Canadian Cancer Society; 2006.
2. Rataj D, Jankowiak B, Krajewska-Kulak E, et al. Quality-of-life evaluation in an interferon therapy after radical surgery in cutaneous melanoma patients. Cancer Nurs 2005;28:172-8.
3. United States, National Institutes of Health, National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) database, 1975-2003. Trends (annual percent change) of SEER incidence rates [Web resource]. Bethesda, MD: National Cancer Institute; n.d. [Available at: seer.cancer.gov/faststats/ sites.php?site=Melanoma%20of%20the%20Skin&stat=Incidence#trend; cited November 28, 2006]
4. Kirkwood JM, Ernstoff MS. Role of interferons in the therapy of melanoma. J Invest Dermatol 1990;95(suppl):180S-4S.
5. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of Intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19: 2370-80.
6. Moschos SJ, Edington HD, Land SR, Rao UN, Shipe-Spotloe J, Kirkwood JM. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006; 24:3164-71.
7. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14: 7-17.
8. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of Intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18:2444-58.
9. Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002;20:3703-18.
10. Trask PC, Paterson AG, Esper P, Pau J, Redman B. Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon. Psychooncology 2004;13:526-36.
11. Greenberg DB, Jonasch E, Gadd MA, et al. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Cancer 2000;89:356-62.
12. Fluck M, Kamanabrou D, Lippold A, Reitz M, Atzpodien J. Dose-dependent treatment benefit in high-risk melanoma patients receiving adjuvant high-dose interferon alfa-2b. Cancer Biother Radiopharm 2005;20:280-9.
13. Kirkwood JM, Ernstoff MS. Potential applications of the interferons in oncology: lessons drawn from studies of human melanoma. Semin Oncol 1986;13:48-56.
14. Kilbridge KL, Weeks JC, Sober AJ, et al. Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol 2001; 19:812-23.
15. Kiley KE, Gale DM. Nursing management of patients with malignant melanoma receiving adjuvant alpha interferon-2b. Clin J Oncol Nurs 1998;2:11-16.
16. Donnelly S. Patient management strategies for interferon alfa-2b as adjuvant therapy of high-risk melanoma. Oncol Nurs Forum 1998;25:921-7.
17. Romanini A, Sarti S, Murr R, et al. Toxicity of adjuvant treatment with high-dose interferon alpha 2b (HD-IFN) in high-risk stage III melanoma patients (pts): the Italian experience [abstract]. Proc Am Soc Clin Oncol 2005;23:7568.